Therapies for patients with previously treated lung cancer

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, two second‐line therapies receive accelerated approval for lung cancer treatment. In addition, omission of postoperative radiotherapy is considered in older patients with breast cancer, and the addition of pembrolizumab to stand care improved event‐free survival for patients with HNSCC.